GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma (original) (raw)
Related papers
Asian Pacific Journal of Cancer Prevention : APJCP, 2019
Background: Due to the prevalence of Hepatocellular carcinoma (HCC) in Saudi Arabia, using new markers to give best diagnostic performance than alpha-feto protein (AFP) are important in early diagnosis. The aim of this work was to compare the significance between serum and mRNA Golgi glypican73 (GP-73) as newly identified diagnostic and prognostic markers for HCC among Saudi patients. Materials and Methods: A total of 300 subjects were divided into: 250 blood samples where 145 samples from HCC, 105 samples from chronic liver cirrhosis (CLC) and 50 normal controls were investigated for serum GP73 (sGP73) by ELISA. GP-73 mRNA from peripheral blood mononuclear cells was amplified by RT-PCR. The sensitivity and specificity of both techniques was compared. Results: Serum Golgi glypican 73 was significantly higher in HCC group compared to cirrhotic and normal controls (p<0.001). Sensitivity and specificity were 95% for sGP-73, 100% and 90% for Golgi glypican 73 mRNA. The combination of...
SERUM GOLGI PROTEIN 73 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. The diagnosis of HCC is mainly based on a combination of abdominal ultrasound and serum alpha fetoprotein (AFP) level. Serum AFP has low sensitivity, serum Golgi protein 73 (sGP73) is a novel and promising biomarker for detection of hepatocellular carcinoma (HCC). However, there are few reports on the predictive values levels of GP73 in diagnosis of HCC. We aimed to evaluate the clinical usefulness of serum GP73 in the diagnosis of HCC. Methods: The study was conducted on 80 patients included 20 patients with chronic hepatitis C (group I), 20 patients with liver cirrhosis (group II divided into two subgroups of equal number compensated and decompensated liver cirrhosis), 40 patients with HCC (group III) in addition to 10 apparently healthy control subjects (group IV). All patients in this study were subjected to full history taking, thorough clinical examination, radiological investigations, routine laboratory investigations and serum AFP in addition to serum GP73 assay by ELISA technique. Results: Assessment of the diagnostic performance of serum GP73 and serum AFP in the present study in diagnosis of HCC revealed that serum GP73 at cutoff of 11.1 ng/mL showed a diagnostic sensitivity of 82.5%, specificity 70%, positive predictive value 78.6%, negative predictive value 75% and the area under the curve (AUC) was 0.8025, Regarding serum AFP at cutoff 320ng/mL showed the diagnostic sensitivity of 79.41%, specificity 60 %, PPV 65.9%%, NPV 75 %, AUC 0.766, This proved the superiority of GP73 estimation over AFP assay in cases of HCC, Conclusion: Serum GP73 had an overall performance better than AFP in detection of HCC in patients with chronic HCV related liver disease so it can be used in diagnosis of HCC.
International Journal of Current Advanced Research, 2017
In the search for serum markers of hepatocellular cancer, several studies try to find a noninvasive marker for diagnosis of hepatocellular carcinoma (HCC) to facilitate the diagnosis and avoid the harmful complications of liver biopsy. Investigators have focused on Golgi protein 73 (GP73); also known as Golgi membrane protein 1 (Golm1) or Golgi Phosphoprotein 2 (Golph2) as non-invasive, available and inexpensive marker for the diagnosis of HCC. The present study aimed to evaluate the serum GP-73 mRNA expression as a marker for HCC diagnosis among Egyptian patients versus alpha fetoprotein. Subjects and Methods: The patients selected from the Hepatology, Gastroenterology and Infectious Diseases Department and from Gastroenterology and Hepatology Unit of Internal Medicine Department, Benha University Hospital. Subjects were classified into three groups: Group I : Included 20 apparently healthy subjects. Group II: Included 20 cirrhotic patients and not complicated by HCC, Group III: Included 40 patients diagnosed as liver cirrhosis complicated by HCC. The serum Golgi Protein 73 (GP73) mRNA was determined by semiquantitative RT-PCR. Results: GP-73mRNA was highly significant higher in HCC patients in comparison to cirrhotic and the control group (P < 0.001). ROC for AFP revealed that the best cut-off value is (>48ng/ml), at this point the sensitivity was 90 %, specificity was 90% and AUC was 0.96. However the ROC for GP-73mRNA expression revealed that the best cut-off value is (>5.11) at this point the sensitivity was 97.5%, specificity was 100% and AUC was 0.99. In conclusion, increased GP-73 mRNA expression could be associated with the presence of HCC and the serum Gp73 mRNA expression was more sensitive and more specific than AFP.
Accuracy of Serum Golgi Protein 73 and Alpha Fetoprotein (AFP) to Diagnose Hepatocellular Carcinoma
https://www.ijrrjournal.com/IJRR\_Vol.8\_Issue.9\_Sep2021/IJRR-Abstract059.html, 2021
Background: Hepatocellular Carcinoma (HCC) is one of the most common malignancies in the liver. Modalities of diagnostic are often an obstacle in HCC surveillance. Alpha fetoprotein (AFP) is one of protein that often used in the diagnostic of HCC in chronic liver disease. Golgi protein 73 (GP73), is one of the candidate biomarkers in early diagnostic of HCC and found in biliary epithelial cells but rarely expressed by normal hepatocytes. Expression of GP73 was reported to be increased in a large number of malignancies. Aims of this study to evaluate differences in Golgi protein 73 serum (sGP73) and AFP in diagnosing hepatocellular carcinoma in patients with liver cirrhosis. Materials and Methods: This cross-sectional study was conducted at Haji Adam Malik Hospital in 2020. Serum level of GP73 and others biomarker was detected using enzymelike immunosorbent assay. Results: From 90 subjects, Liver cirrhosis and HCC group had significantly higher AFP than the control group. AFP was superior in determining HCC to GP73. At a cut off value of > 394.5.00 ng/mL, AFP yielded a sensitivity of 83.3% and specificity of 67%, for discriminating liver cirrhosis and HCC (AUC 0.84), while GP73 with cut off value of > 82.5 ng/mL, sensitivity of 70% and specificity of 57% (AUC 0.74). Conclusion: GP73 was significantly higher in HCC patients in comparison to non-HCC patients and healthy population. Compared with alpha fetoprotein, GP73 was superior in discriminating HCC in healthy population but inferior in group of liver cirrhosis.
The Egyptian Journal of Internal Medicine, 2017
Background and aim Hepatocellular carcinoma (HCC) is the third cause of cancer-related mortality. α-fetoprotein (AFP) is not a highly sensitive marker for predicting HCC despite its high specificity. Serum Golgi protein-73 (sGP73) seems to be promising new marker. This study aimed at evaluating the role of sGP73 alone and in combination with AFP for diagnosing HCC. Patients and methods This study was conducted on 90 Egyptian patients who were equally divided into two groups. Group 1 included 45 patients with hepatitis C virus-related liver cirrhosis without clinical or radiological evidence of HCC, and group 2 included 45 patients diagnosed as having HCC by triphasic abdominal computed tomography. Serum AFP and GP73 were measured using enzyme-linked immunosorbent assay. Results A cutoff value greater than or equal to 40 ng/ml for AFP had a sensitivity of 51.1%, specificity of 97.8%, and area under the curve (AUC) of 0.802. sGP73 with a cutoff value greater than or equal to 1.4 ng/ml yielded a sensitivity of 75.6%, specificity of 97.8%, diagnostic accuracy of 86.7%, and AUC of 0.908. The combined use of AFP and sGp73 led to an increase in sensitivity to 84.4%, specificity to 95.6%, diagnostic accuracy to 90%, and AUC to 0.947. Conclusion The combined use of AFP and sGp73 could increase the sensitivity and specificity for HCC diagnosis.
Asian Pacific Journal of Cancer Prevention, 2019
Background: Due to the prevalence of Hepatocellular carcinoma (HCC) in Saudi Arabia, using new markers to give best diagnostic performance than alpha-feto protein (AFP) are important in early diagnosis. The aim of this work was to compare the significance between serum and mRNA Golgi glypican73 (GP-73) as newly identified diagnostic and prognostic markers for HCC among Saudi patients. Materials and Methods: A total of 300 subjects were divided into: 250 blood samples where 145 samples from HCC, 105 samples from chronic liver cirrhosis (CLC) and 50 normal controls were investigated for serum GP73 (sGP73) by ELISA. GP-73 mRNA from peripheral blood mononuclear cells was amplified by RT-PCR. The sensitivity and specificity of both techniques was compared. Results: Serum Golgi glypican 73 was significantly higher in HCC group compared to cirrhotic and normal controls (p<0.001). Sensitivity and specificity were 95% for sGP-73, 100% and 90% for Golgi glypican 73 mRNA. The combination of sensitivity between AFP and sGP73 was 80% and 95% respectively. Conclusion: Both serum Golgi glypican-73 and GP-73Mrna are good diagnostic biomarkers for early detection of HCC in Saudi patients. RT-PCR is more accurate and sensitive (100%) than ELISA (95%) in detecting Golgi glypican 73.
The predictive value of Golgi protein 73 in differentiating benign from malignant liver tumors
PloS one, 2014
In the work up of primary solid liver lesions it is essential to differentiate correctly between benign and malignant tumors, such as hepatocellular adenoma (HCA) and hepatocellular carcinoma (HCC) respectively. A promising new marker to detect HCC is Golgi Protein 73 (GP73). Studies comparing patients with HCC and cirrhosis with normal controls suggested that GP73 is specific for patients with HCC; however, patients with other liver tumors were not included. We therefore studied the predictive value of GP73 in differentiating between solid benign and malignant liver tumors. This study included 264 patients: 88 patients with HCC, 88 with hepatocellular adenoma (HCA), and 88 with focal nodal hyperplasia (FNH). A blood sample was collected from each patient to measure GP73 levels using a quantitative ELISA assay and differences in outcome between subgroups were compared. The receiver operating characteristic (ROC) curve, sensitivity and specificity of GP73 were calculated and compared...
Medical Journal Armed Forces India, 2021
Background: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. Early detection of HCC is always a challenging task for physicians. Serum Golgi protein 73 (GP73) is considered a potential tumor marker for the detection of HCC. However, the diagnostic value of GP73 for the HCC diagnosis is still controversial. This research was designed to assess the diagnostic efficacy of GP73 as a diagnostic tool for HCC in cases with hepatitis C virus-related cirrhosis. Methods: Eighty-seven subjects were allocated into four different groups in this prospective research (HCC, liver cirrhosis, chronic hepatitis C, and healthy control group). Serum alpha-fetoprotein (AFP) and GP73 were tested for all subjects in the study. Detection of focal hepatic lesions was based on imaging by abdominal ultrasonography and triphasic computed tomography. Results: The cutoff values for GP73 and AFP were 534.5 ng/L and 32 ng/mL, respectively. The specificity of GP73 was 87%, and the sensitivity was 88%, while the specificity and sensitivity of AFP levels were 80% and 72%, respectively. The negative predictive value of GP73 was 87.5%, and the positive predictive value of GP73 was 84.6%, while the same parameters of AFP were 73.1% and 75%, respectively. Conclusion: Serum Golgi protein 73 could be a valuable biomarker and a useful diagnostic tool for the early diagnosis of HCC in cases of hepatitis C virus-related cirrhosis.
Golgi Protein 73 as a Diagnostic Tool for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients
Afro-Egyptian Journal of Infectious and Endemic Diseases
Results: The maximum cutoff levels for GP73 was 534.5 ng/L and in comparison the cutoff AFP level was 32 ng/mL. For GP73, the sensitivity was 88% and specificity 88% while the sensitivity of AFP was 72% and the specificity of AFP was 80%. The +v predictive value of GP73 and the-ve predictive value of GP73 were 84.6% and 87.5% while the same values of AFP were 75% and 73.1%, respectively. Conclusion: It was found that serum GP73 was up-regulated in HCC and we can use it as a good biomarker for early detection and for screening of malignant liver lesions in cirrhotic patients due chronic HCV infection and it would be more accurate and effective tool than serum AFP in discriminating the malignant liver lesion from the chronic hepatitis.